Jin-Xue He

Jin-Xue He

Auto-generated profile, based on publicly available information

Jin-Xue He

State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
LWLi‐Min Wang
Li‐Min Wang
PWPingyuan Wang
Pingyuan Wang
XCXiao‐Min Chen
Xiao‐Min Chen
HYHui Yang
Hui Yang
SSShan‐Shan Song
Shan‐Shan Song
JHJin‐Xue He
Jin‐Xue He
Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generation PARPi with high affinity against multiple PARPs, including PARP1, PARP2, and PARP7, displays high antitumor activities against PARPi‐sensitive and ‐resistant cells with homologous recombination (HR) deficiency both in vitro and in vivo . Thioparib treatment elicited PARP1‐dependent DNA damage and replication stress, causing S‐phase arrest and apoptosis. Conversely, thioparib strongly inhibited HR‐mediated DNA repair while increasing RAD51 foci formation. Notably, the on‐target inhibition of PARP7 by thioparib‐activated STING/TBK1‐dependent phosphorylation of STAT1, triggered a strong induction of type I interferons (IFNs), and resulted in tumor growth retardation in an immunocompetent mouse model. However, the inhibitory effect of thioparib on tumor growth was more pronounced in PARP1 knockout mice, suggesting that a specific PARP7 inhibitor, rather than a pan inhibitor such as thioparib, would be more relevant for clinical applications. Finally, genome‐scale CRISPR screening identified PARP1 and MCRS1 as genes capable of modulating thioparib sensitivity. Taken together, thioparib, a next‐generation PARPi acting on both DNA damage response and antitumor immunity, serves as a therapeutic potential for treating hyperactive HR tumors, including those resistant to earlier‐generation PARPi.

15 February 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
NZNing Zhang
Ning Zhang
YTYu-Nan Tian
Yu-Nan Tian
LZLi-Na Zhou
Li-Na Zhou
MLMeng-Zhu Li
Meng-Zhu Li
HCHua-Dong Chen
Hua-Dong Chen
JHJin-Xue He
Jin-Xue He
Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PARPi). To overcome resistance to PARPi and to broaden their clinical use, we performed high-throughput screening of 99 anticancer drugs in combination with PARPi to identify potential therapeutic combinations. Here, we found that GSK3 inhibitors (GSK3i) exhibited a strong synergistic effect with PARPi in a panel of colorectal cancer (CRC) cell lines with diverse genetic backgrounds. The combination of GSK3β and PARP inhibition causes replication stress and DNA double-strand breaks, resulting in increased anaphase bridges and abnormal spindles. Mechanistically, inhibition or genetic depletion of GSK3β was found to impair the HRR of DNA and reduce the mRNA and protein level of BRCA1. Finally, we demonstrated that inhibition or depletion of GSK3β could enhance the in vivo sensitivity to simmiparib without toxicity. Our results provide a mechanistic understanding of the combination of PARP and GSK3 inhibition, and support the clinical development of this combination therapy for CRC patients.

17 April 2017 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
ZYZhong-Min Yang
Zhong-Min Yang
XLXue-Mei Liao
Xue-Mei Liao
YCYi Chen
Yi Chen
YSYan-Yan Shen
Yan-Yan Shen
XYXin-Ying Yang
Xin-Ying Yang
ZMZe-Hong Miao
Ze-Hong Miao

28 June 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Muzaffar Bakhadirovich KayumovMuzaffar Bakhadirovich Kayumov
Muzaffar Bakhadirovich Kayumov
LJLi Jia
Li Jia
APAzizbek Pardaev
Azizbek Pardaev
SSShan-Shan Song
Shan-Shan Song
SMSharafitdin Mirzaakhmedov
Sharafitdin Mirzaakhmedov
AZAo zhang
Ao zhang

22 December 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
YWYu‐Ting Wang
Yu‐Ting Wang
BYBo Yuan
Bo Yuan
HCHua‐Dong Chen
Hua‐Dong Chen
LXLin Xu
Lin Xu
YTYu‐Nan Tian
Yu‐Nan Tian
ZMZe-Hong Miao
Ze-Hong Miao
With increasing uses of poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) for cancer therapy, understanding their resistance is becoming urgent. However, acquired PARPi resistance in the phosphatase and tensin homolog (PTEN)‐deficient background is poorly understood. We generated 3 PARPi‐resistant PTEN‐deficient glioblastoma U251 variants separately with olaparib (U251/OP), talazoparib (U251/TP) and simmiparib (U251/SP). These variants displayed consistent resistance (2.46‐71.78‐fold) to all 5 PARPi, including niraparib and rucaparib, and showed higher degrees of resistance to the PARPi to which the parental cells were more sensitive. The resistance was characteristic of fast emergence and high stability. However, the resistance acquirement did not cause an increasingly aggressive phenotype. The resistance was not correlated to various factors, including PTEN mutations. The PARPi‐treated variants produced less γH2AX and G2/M arrest. Consistently, loss of 53BP1 occurred in all variants and its compensation enhanced their sensitivity to PARPi by approximately 76%. The variants revealed slightly different cross‐resistance profiles to 13 non‐PARPi anticancer drugs. All were resistant to Ara‐C (6‐8‐fold) but showed differential resistance to 5‐fluorouracil, gemcitabine and paclitaxel. Almost no resistance was observed to the rest drugs, including cisplatin. SAMHD1 was overexpressed in all the variants and its knockout completely restored their sensitivity to Ara‐C but did not affect their PARPi sensitivity. The present study demonstrates a consistent resistance profile to PARPi and a unique cross‐resistance profile to non‐PARPi drugs in different PARPi‐resistant U251 cells and reveals 53BP1 loss and SAMHD1 overexpression as the primary mechanisms responsible for their resistance to PARPi and Ara‐C, respectively. These effects probably result from heritable gene change(s) caused by persistent PARPi exposure.

14 June 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHongrui Li
Hongrui Li
BLBen-Jin Liu
Ben-Jin Liu
JXJiahao Xu
Jiahao Xu
SSShan-Shan Song
Shan-Shan Song
RBRuixian Ba
Ruixian Ba
BXBing Xiong
Bing Xiong